Cargando…
Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy
Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663525/ https://www.ncbi.nlm.nih.gov/pubmed/26561833 http://dx.doi.org/10.3390/toxins7114645 |
_version_ | 1782403314725421056 |
---|---|
author | Blaszczyk, Izabela Foumani, Nazli Poorsafar Ljungberg, Christina Wiberg, Mikael |
author_facet | Blaszczyk, Izabela Foumani, Nazli Poorsafar Ljungberg, Christina Wiberg, Mikael |
author_sort | Blaszczyk, Izabela |
collection | PubMed |
description | Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP. |
format | Online Article Text |
id | pubmed-4663525 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-46635252015-12-10 Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy Blaszczyk, Izabela Foumani, Nazli Poorsafar Ljungberg, Christina Wiberg, Mikael Toxins (Basel) Article Botulinum toxin A (BoNT-A) injections for treatment of spasticity in patients with cerebral palsy (CP) have been used for about two decades. The treatment is considered safe but a low frequency of adverse events (AE) has been reported. A good method to report AEs is necessary to verify the safety of the treatment. We decided to use an active surveillance of treatment-induced harm using a questionnaire we created. We studied the incidence of reported AEs and side effects in patients with CP treated with BoNT-A. We investigated the relationship between the incidence of AEs or side effects and gender, age, weight, total dose, dose per body weight, Gross Motor Function Classification System (GMFCS) and number of treated body parts. Seventy-four patients with CP participated in our study. In 54 (51%) of 105 BoNT-A treatments performed in 45 (61%) patients, there were 95 AEs and side effects reported, out of which 50 were generalized and/or focal distant. Severe AEs occurred in three patients (4%), and their BoNT-A treatment was discontinued. Consecutive collection of the AE and side-effect incidence using our questionnaire can increase the safety of BoNT-A treatment in patients with CP. MDPI 2015-11-06 /pmc/articles/PMC4663525/ /pubmed/26561833 http://dx.doi.org/10.3390/toxins7114645 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Blaszczyk, Izabela Foumani, Nazli Poorsafar Ljungberg, Christina Wiberg, Mikael Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title_full | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title_fullStr | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title_full_unstemmed | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title_short | Questionnaire about the Adverse Events and Side Effects Following Botulinum Toxin A Treatment in Patients with Cerebral Palsy |
title_sort | questionnaire about the adverse events and side effects following botulinum toxin a treatment in patients with cerebral palsy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663525/ https://www.ncbi.nlm.nih.gov/pubmed/26561833 http://dx.doi.org/10.3390/toxins7114645 |
work_keys_str_mv | AT blaszczykizabela questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT foumaninazlipoorsafar questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT ljungbergchristina questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy AT wibergmikael questionnaireabouttheadverseeventsandsideeffectsfollowingbotulinumtoxinatreatmentinpatientswithcerebralpalsy |